Gastroesophageal Reflux Incites Interstitial Lung Disease in Systemic Sclerosis: Clinical, Radiologic, Histopathologic, and Treatment Evidence

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 3, 2010, Pages 241-249

  Christmann, Romy B ^a   Wells, Athol U ^b,c   Capelozzi, Vera L ^a   Silver, Richard M ^d  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Centrilobular fibrosis; Gastroesophageal reflux; Interstitial lung disease; Scleroderma; Systemic sclerosis; Treatment

Indexed keywords

BILE ACID; BIOLOGICAL MARKER; CELL PROTEIN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; PENTETIC ACID; PEPSIN A; PROKINETIC AGENT; PROTEIN KL 6; PROTON PUMP INHIBITOR; UNCLASSIFIED DRUG;

BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA; CAUSE OF DEATH; CELL DAMAGE; CENTRILOBULAR FIBROSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG CONTRAINDICATION; DRUG MEGADOSE; ESOPHAGOGRAPHY; ESOPHAGOSCOPY; ESOPHAGUS DILATATION; ESOPHAGUS MANOMETRY; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; FOLLOW UP; FORCED VITAL CAPACITY; GASTROINTESTINAL REFLUX; HISTOPATHOLOGY; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; LUNG ALVEOLUS EPITHELIUM; LUNG BIOPSY; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG LAVAGE; NONSPECIFIC INTERSTITIAL PNEUMONIA; PATHOPHYSIOLOGY; PH MEASUREMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ASPIRATION; REVIEW; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TOTAL LUNG CAPACITY; UNSPECIFIED SIDE EFFECT;

BIOPSY; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; MANOMETRY; RESPIRATORY FUNCTION TESTS; SCLERODERMA, SYSTEMIC;

EID: 78649448568     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.03.002     Document Type: Review

References (52)

1. Tamby M.C., Chanseaud Y., Guillevin L., Mouthon L. New insights into the pathogenesis of systemic sclerosis. Autoimmun Rev 2003, 2(3):152-157.
2. Abu-Shakra M., Guillemin F., Lee P. Gastrointestinal manifestations of systemic sclerosis. Semin Arthritis Rheum 1994, 24(1):29-39.
3. Marie I., Levesque H., Ducrotte P., Denis P., Hellot M.F., Benichou J., et al. Gastric involvement in systemic sclerosis: a prospective study. Am J Gastroenterol 2001, 96(1):77-83.
4. Sjogren R.W. Gastrointestinal features of scleroderma. Curr Opin Rheumatol 1996, 8(6):569-575.
5. Sjogren R.W. Gastrointestinal motility disorders in scleroderma. Arthritis Rheum 1994, 37(9):1265-1282.
6. Steen V.D., Owens G.R., Fino G.J., Rodnan G.P., Medsger T.A. Pulmonary involvement in systemic sclerosis (scleroderma). Arthritis Rheum 1985, 28(7):759-767.
7. McCarthy D.S., Baragar F.D., Dhingra S., Sigurdson M., Sutherland J.B., Rigby M., et al. The lungs in systemic sclerosis (scleroderma): a review and new information. Semin Arthritis Rheum 1988, 17(4):271-283.
8. Simeon C.P., Armadans L., Fonollosa V., Solans R., Selva A., Villar M., et al. Mortality and prognostic factors in Spanish patients with systemic sclerosis. Rheumatology (Oxford) 2003, 42(1):71-75.
9. Ioannidis J.P., Vlachoyiannopoulos P.G., Haidich A.B., Medsger T.A., Lucas M., Michet C.J., et al. Mortality in systemic sclerosis: an international meta-analysis of individual patient data. Am J Med 2005, 118(1):2-10.
10. Bryan C., Knight C., Black C.M., Silman A.J. Prediction of five-year survival following presentation with scleroderma: development of a simple model using three disease factors at first visit. Arthritis Rheum 1999, 42(12):2660-2665.
11. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med 2002, 165(2):277-304. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias.
12. Fujita J., Yoshinouchi T., Ohtsuki Y., Tokuda M., Yang Y., Yamadori I., et al. Non-specific interstitial pneumonia as pulmonary involvement of systemic sclerosis. Ann Rheum Dis 2001, 60(3):281-283.
13. Bouros D., Wells A.U., Nicholson A.G., Colby T.V., Polychronopoulos V., Pantelidis P., et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002, 165(12):1581-1586.
14. Kim D.S., Yoo B., Lee J.S., Kim E.K., Lim C.M., Lee S.D., et al. The major histopathologic pattern of pulmonary fibrosis in scleroderma is nonspecific interstitial pneumonia. Sarcoidosis Vasc Diffuse Lung Dis 2002, 19(2):121-127.
15. Antoniou K.M., Wells A.U. Scleroderma lung disease: evolving understanding in light of newer studies. Curr Opin Rheumatol 2008, 20(6):686-691.
16. Highland K.B., Silver R.M. New developments in scleroderma interstitial lung disease. Curr Opin Rheumatol 2005, 17(6):737-745.
17. Gilson M., Zerkak D., Wipff J., Dusser D., Dinh-Xuan A.T., Abitbol V., et al. Prognostic factors for lung function in systemic sclerosis: prospective study of 105 cases. Eur Respir J 2010, 35(1):112-117.
18. Moran T.J. Experimental aspiration pneumonia. IV. Inflammatory and reparative changes produced by intratracheal injections of autologous gastric juice and hydrochloric acid. AMA Arch Pathol 1955, 60(2):122-129.
19. Donnelly R.J., Berrisford R.G., Jack C.I., Tran J.A., Evans C.C. Simultaneous tracheal and esophageal pH monitoring: investigating reflux-associated asthma. Ann Thorac Surg 1993, 56(5):1029-1033. discussion 1034.
20. Ducolone A., Vandevenne A., Jouin H., Grob J.C., Coumaros D., Meyer C., et al. Gastroesophageal reflux in patients with asthma and chronic bronchitis. Am Rev Respir Dis 1987, 135(2):327-332.
21. Mansfield L.E. Gastroesophageal reflux and diseases of the respiratory tract: a review. J Asthma 1989, 26(5):271-278.
22. Schnatz P.F., Castell J.A., Castell D.O. Pulmonary symptoms associated with gastroesophageal reflux: use of ambulatory pH monitoring to diagnose and to direct therapy. Am J Gastroenterol 1996, 91(9):1715-1718.
23. Shimizu Y., Dobashi K., Zhao J.J., Kawata T., Ono A., Yanagitani N., et al. Proton pump inhibitor improves breath marker in moderate asthma with gastroesophageal reflux disease. Respiration 2007, 74(5):558-564.
24. Kiljander T.O., Salomaa E.R., Hietanen E.K., Ovaska J., Helenius H., Liippo K. Gastroesophageal reflux and bronchial responsiveness: correlation and the effect of fundoplication. Respiration 2002, 69(5):434-439.
25. Cantu E., Appel J.Z., Hartwig M.G., Woreta H., Green C., Messier R., et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg 2004, 78(4):1142-1151. discussion 1142-51.
26. Tobin R.W., Pope C.E., Pellegrini C.A., Emond M.J., Sillery J., Raghu G. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998, 158(6):1804-1808.
27. Raghu G., Freudenberger T.D., Yang S., Curtis J.R., Spada C., Hayes J., et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J 2006, 27(1):136-142.
28. Patti M.G., Tedesco P., Golden J., Hays S., Hoopes C., Meneghetti A., et al. Idiopathic pulmonary fibrosis: how often is it really idiopathic?. J Gastrointest Surg 2005, 9(8):1053-1056. discussion 1056-8.
29. Raghu G., Yang S.T., Spada C., Hayes J., Pellegrini C.A. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006, 129(3):794-800.
30. Appel J.Z., Lee S.M., Hartwig M.G., Li B., Hsieh C.C., Cantu E., et al. Characterization of the innate immune response to chronic aspiration in a novel rodent model. Respir Res 2007, 8:87.
31. Farrell S., McMaster C., Gibson D., Shields M.D., McCallion W.A. Pepsin in bronchoalveolar lavage fluid: a specific and sensitive method of diagnosing gastro-oesophageal reflux-related pulmonary aspiration. J Pediatr Surg 2006, 41(2):289-293.
32. Matsuse T., Oka T., Kida K., Fukuchi Y. Importance of diffuse aspiration bronchiolitis caused by chronic occult aspiration in the elderly. Chest 1996, 110(5):1289-1293.
33. Starosta V., Kitz R., Hartl D., Marcos V., Reinhardt D., Griese M. Bronchoalveolar pepsin, bile acids, oxidation, and inflammation in children with gastroesophageal reflux disease. Chest 2007, 132(5):1557-1564.
34. Johnson D.A., Drane W.E., Curran J., Cattau E.L., Ciarleglio C., Khan A., et al. Pulmonary disease in progressive systemic sclerosis. A complication of gastroesophageal reflux and occult aspiration?. Arch Intern Med 1989, 149(3):589-593.
35. Lock G., Pfeifer M., Straub R.H., Zeuner M., Lang B., Scholmerich J., et al. Association of esophageal dysfunction and pulmonary function impairment in systemic sclerosis. Am J Gastroenterol 1998, 93(3):341-345.
36. Marie I., Dominique S., Levesque H., Ducrotte P., Denis P., Hellot M.F., et al. Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Rheum 2001, 45(4):346-354.
37. Marie I., Ducrotte P., Denis P., Hellot M.F., Levesque H. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006, 24(11-12):1593-1601.
38. Tutuian R., Castell D.O. Use of multichannel intraluminal impedance to document proximal esophageal and pharyngeal nonacidic reflux episodes. Am J Med 2003, 115(Suppl 3A):119S-123S.
39. Savarino E., Bazzica M., Zentilin P., Pohl D., Parodi A., Cittadini G., et al. Gastroesophageal reflux and pulmonary fibrosis in scleroderma: a study using pH-impedance monitoring. Am J Respir Crit Care Med 2009, 179(5):408-413.
40. Troshinsky M.B., Kane G.C., Varga J., Cater J.R., Fish J.E., Jimenez S.A., et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994, 121(1):6-10.
41. Barnes T.W., Vassallo R., Tazelaar H.D., Hartman T.E., Ryu J.H. Diffuse bronchiolar disease due to chronic occult aspiration. Mayo Clin Proc 2006, 81(2):172-176.
42. Mukhopadhyay S., Katzenstein A.L. Pulmonary disease due to aspiration of food and other particulate matter: a clinicopathologic study of 59 cases diagnosed on biopsy or resection specimens. Am J Surg Pathol 2007, 31(5):752-759.
43. de Souza R.B., Borges C.T., Capelozzi V.L., Parra E.R., Jatene F.B., Kavakama J., et al. Centrilobular fibrosis: an underrecognized pattern in systemic sclerosis. Respiration 2009, 77(4):389-397.
44. de Carvalho M.E., Kairalla R.A., Capelozzi V.L., Deheinzelin D., do Nascimento Saldiva P.H., de Carvalho C.R. Centrilobular fibrosis: a novel histological pattern of idiopathic interstitial pneumonia. Pathol Res Pract 2002, 198(9):577-583.
45. Bhalla M., Silver R.M., Shepard J.A., McLoud T.C. Chest CT in patients with scleroderma: prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. AJR Am J Roentgenol 1993, 161(2):269-272.
46. Vonk M.C., van Die C.E., Snoeren M.M., Bhansing K.J., van Riel P.L., Fransen J., et al. Oesophageal dilatation on high-resolution computed tomography scan of the lungs as a sign of scleroderma. Ann Rheum Dis 2008, 67(9):1317-1321.
47. Imokawa S., Sato A., Hayakawa H., Kotani M., Urano T., Takada A. Tissue factor expression and fibrin deposition in the lungs of patients with idiopathic pulmonary fibrosis and systemic sclerosis. Am J Respir Crit Care Med 1997, 156(2 Pt. 1):631-636.
48. Mogulkoc N., Brutsche M.H., Bishop P.W., Murby B., Greaves M.S., Horrocks A.W., et al. Pulmonary (99m)Tc-DTPA aerosol clearance and survival in usual interstitial pneumonia (UIP). Thorax 2001, 56(12):916-923.
49. Kon O.M., Daniil Z., Black C.M., du Bois R.M. Clearance of inhaled technetium-99m-DTPA as a clinical index of pulmonary vascular disease in systemic sclerosis. Eur Respir J 1999, 13(1):133-136.
50. Fanti S., De Fabritiis A., Aloisi D., Dondi M., Marengo M., Compagnone G., et al. Early pulmonary involvement in systemic sclerosis assessed by technetium-99m-DTPA clearance rate. J Nucl Med 1994, 35(12):1933-1936.
51. Satoh H., Kurishima K., Ishikawa H., Ohtsuka M. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases. J Intern Med 2006, 260(5):429-434.
52. Hant F.N., Ludwicka-Bradley A., Wang H.J., Li N., Elashoff R., Tashkin D.P., et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol 2009, 36(4):773-780.